How to Position Pasireotide LAR Treatment in Acromegaly | Zendy

Eva C Coopmans | Zendy; Ammar Muhammad | Zendy; A. J. van der Lely | Zendy; J. A. M. J. L. Janssen | Zendy; Sebastian Neggers | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

How to Position Pasireotide LAR Treatment in Acromegaly

Author(s) -

Eva C Coopmans,

Ammar Muhammad,

A. J. van der Lely,

J. A. M. J. L. Janssen,

Sebastian Neggers

Publication year - 2019

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2018-01979

Subject(s) - pasireotide , acromegaly , medicine , pegvisomant , somatostatin , octreotide , oncology , growth hormone , hormone

Pasireotide long-acting release (LAR) is a somatostatin multireceptor ligand, and in the current consensus criteria pasireotide LAR is considered the second-line medical treatment for acromegaly. We present in this article our recommendations to define the position of pasireotide LAR in the treatment of acromegaly and provide recommendations for the management of pasireotide-induced hyperglycemia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research